Mar 31 2008
Advanced Medical Optics, Inc. (AMO), a global leader in ophthalmic surgical devices and eye care products, today announced the U.S. introduction of blink Tears, a new line of over-the-counter lubricating eye drops for the estimated 40 percent of Americans who suffer from occasional or chronic dry eye symptoms.
AMO developed a unique, advanced formula for blink® Tears lubricating eye drops that includes a blend of ingredients naturally found in the eye. Product benefits include:
- long-lasting relief with less blurring of vision;
- up to 60-minute moisture retention time;
- restores tear film with each blink;
- improved tear film stability;
- adapts to an individual’s dry eye needs by thickening when the eye is open, and thinning when the eye blinks;
- promotion of health and well-being of the eye.
“Dry eye is one of the most common disorders we see as ophthalmologists and yet it is also one of the most under-diagnosed,” said Eric D. Donnenfeld, M.D., who is in private practice with Ophthalmic Consultants of Long Island and is a trustee of Dartmouth Medical School. “This is unfortunate, because treating dry eye effectively can improve our patients' quality of vision and their quality of life.”
“I believe that blink® Tears will be a significant improvement to our treatment regimen for managing the symptoms of dry eye,” continued Dr. Donnenfeld. “The unique formulation of blink® Tears distinguishes it from other currently available artificial tears because it can provide both a long duration of effect as well as superior visual clarity. We know that patients are more likely to use artificial tears as directed if they feel they are getting a longer-lasting benefit from the drop.”
“The introduction of blink® Tears lubricating eye drops is our first entree into the dry eye category and marks an important expansion of AMO’s complete refractive solution of eye care products,” said AMO Chairman and CEO Jim Mazzo. “It will be used to relieve mild to moderate dry eye whether used alone or in conjunction with ophthalmic pharmaceutical therapies.”